NCT04314219View on ClinicalTrials.gov

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

August 15, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Acute Lymphoblastic Leukemia (ALL) in Complete RemissionAcute Myeloid Leukemia (AML) in Remission
Interventions
DRUG

Cyclophosphamide 50mg

Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5

DRUG

Methotrexate

Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6

Trial Locations (1)

Unknown

RECRUITING

King Faisal Specialist Hospital & Research Center, Riyadh

All Listed Sponsors
lead

King Faisal Specialist Hospital & Research Center

OTHER